Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

SCORE2 Screening Tool for Cardiovascular Risk Assessment in Psoriasis-A Case-Control Study

T. Kampe, J. Baloghová, P. Kolarčik, K. Rimárová, E. Dorko

. 2024 ; 13 (11) : . [pub] 20240530

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24012669

Grantová podpora
This work was supported by grants KEGA 008UPJŠ-4/2020; 010UPJŠ-4/2021; 003UPJŠ-4/2024 and 001UPJŠ-4/2024- All 4 KEGA grants represent financial support from of the Ministry of Education, Science, Research and Sport of the Slovak Republic. Ministry of Education, Science, Research and Sport of the Slovak Republic

Background: Psoriasis is a common, T-cell-mediated inflammatory and immune-mediated skin disease. Numerous studies confirmed that patients with psoriasis have a significant frequency of cardiovascular (CV) risk factors and CV diseases (CVDs). Risk stratification is helpful in light of the elevated risk of CVD in psoriasis patients. SCORE2 and SCORE2-OP, a new algorithm derived, calibrated and validated to predict the 10-year risk of first-onset CVD in European populations, enhances the identification of individuals at higher risk of developing CVD across Europe. Objective: Using the SCORE2 and SCORE2-OP scoring systems, the current study objective was to evaluate CV risk in Slovak psoriasis patients and the relationship between CV risk and psoriasis features in a real-world setting. Results: A case-control study was conducted involving 115 outpatients with plaque psoriasis and 66 age- and gender-matched controls with skin conditions other than psoriasis. Patients with psoriasis had significantly higher mean SCORE2 values. In the age group up to 50 years, more psoriasis patients were classified as moderate risk than controls (33.8% vs. 13.6%, p = 0.010); the high-risk category was dominated by psoriasis patients. Analysing the relationship between CV risk and selected variables, we determined, using linear regression, the dependence of the SCORE2 risk score on gender in the age group up to 50 years, on age in both age groups, on waist circumference (WC) in the category up to 50 years and on the duration and severity of psoriasis in both age groups using linear regression. For individuals older than 70, we estimated the SCORE2-OP risk score, with the average risk score being 19.5 ± 4.95. We did not observe controls with a high risk score. Psoriasis patients were more likely to be smokers and had significantly higher mean values for body mass index (BMI), WC, total cholesterol (TC), low-density lipoprotein (LDL) and systolic blood pressure (BP). Conclusions: Because CV risk factors and psoriasis are strongly related, the importance of CV risk stratification is growing, and initiating preventive lifestyle changes or therapeutic interventions in patients with psoriasis is warranted.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24012669
003      
CZ-PrNML
005      
20240726151339.0
007      
ta
008      
240723s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jcm13113237 $2 doi
035    __
$a (PubMed)38892947
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kampe, Tomáš $u Department of Dermatovenerology, Faculty of Medicine, University Hospital, P. J. Safarik University, 040 01 Kosice, Slovakia
245    10
$a SCORE2 Screening Tool for Cardiovascular Risk Assessment in Psoriasis-A Case-Control Study / $c T. Kampe, J. Baloghová, P. Kolarčik, K. Rimárová, E. Dorko
520    9_
$a Background: Psoriasis is a common, T-cell-mediated inflammatory and immune-mediated skin disease. Numerous studies confirmed that patients with psoriasis have a significant frequency of cardiovascular (CV) risk factors and CV diseases (CVDs). Risk stratification is helpful in light of the elevated risk of CVD in psoriasis patients. SCORE2 and SCORE2-OP, a new algorithm derived, calibrated and validated to predict the 10-year risk of first-onset CVD in European populations, enhances the identification of individuals at higher risk of developing CVD across Europe. Objective: Using the SCORE2 and SCORE2-OP scoring systems, the current study objective was to evaluate CV risk in Slovak psoriasis patients and the relationship between CV risk and psoriasis features in a real-world setting. Results: A case-control study was conducted involving 115 outpatients with plaque psoriasis and 66 age- and gender-matched controls with skin conditions other than psoriasis. Patients with psoriasis had significantly higher mean SCORE2 values. In the age group up to 50 years, more psoriasis patients were classified as moderate risk than controls (33.8% vs. 13.6%, p = 0.010); the high-risk category was dominated by psoriasis patients. Analysing the relationship between CV risk and selected variables, we determined, using linear regression, the dependence of the SCORE2 risk score on gender in the age group up to 50 years, on age in both age groups, on waist circumference (WC) in the category up to 50 years and on the duration and severity of psoriasis in both age groups using linear regression. For individuals older than 70, we estimated the SCORE2-OP risk score, with the average risk score being 19.5 ± 4.95. We did not observe controls with a high risk score. Psoriasis patients were more likely to be smokers and had significantly higher mean values for body mass index (BMI), WC, total cholesterol (TC), low-density lipoprotein (LDL) and systolic blood pressure (BP). Conclusions: Because CV risk factors and psoriasis are strongly related, the importance of CV risk stratification is growing, and initiating preventive lifestyle changes or therapeutic interventions in patients with psoriasis is warranted.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Baloghová, Janette $u Department of Dermatovenerology, Faculty of Medicine, University Hospital, P. J. Safarik University, 040 01 Kosice, Slovakia $1 https://orcid.org/0000000344705777
700    1_
$a Kolarčik, Peter $u Department of Health Psychology and Research Methodology, Faculty of Medicine, P. J. Safarik University, 040 01 Kosice, Slovakia $u Olomouc University Social Health Institute, Palacky University Olomouc, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000345045256
700    1_
$a Rimárová, Kvetoslava $u Department of Public Health and Hygiene, Faculty of Medicine, P. J. Safarik University, 040 01 Kosice, Slovakia $1 https://orcid.org/0000000343640553
700    1_
$a Dorko, Erik $u Department of Public Health and Hygiene, Faculty of Medicine, P. J. Safarik University, 040 01 Kosice, Slovakia
773    0_
$w MED00195462 $t Journal of clinical medicine $x 2077-0383 $g Roč. 13, č. 11 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38892947 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151331 $b ABA008
999    __
$a ok $b bmc $g 2125441 $s 1224532
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 13 $c 11 $e 20240530 $i 2077-0383 $m Journal of clinical medicine $n J Clin Med $x MED00195462
GRA    __
$a This work was supported by grants KEGA 008UPJŠ-4/2020; 010UPJŠ-4/2021; 003UPJŠ-4/2024 and 001UPJŠ-4/2024- All 4 KEGA grants represent financial support from of the Ministry of Education, Science, Research and Sport of the Slovak Republic. $p Ministry of Education, Science, Research and Sport of the Slovak Republic
LZP    __
$a Pubmed-20240723

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...